Cesca Therapeutics (KOOL) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Cesca Therapeutics Reports Second Quarter Fiscal 2016 Results and Provides a Status Update to Investors
February 16, 2016 4:06 PM ESTRANCHO CORDOVA, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ: KOOL) (the Company), an autologous cell-based regenerative medicine company, today reported financial results for the second quarter of fiscal 2016 and provided an update to investors. The update included details of the closing of the previously announced $15 million strategic investment made in the Company by the Boyalife Group (Boyalife), a discussion of the scope of Boyalifes healthcare-related business interests and an update on the status of Cescas FDA approved Phase III pivotal trial for the treatment of no-option patients with critical limb ischemia... More
